HUGE - FSD Pharma Interim Results Shows Lucid-MS Compound to be Safe and Well Tolerated

2023-09-18 10:21:50 ET

(24/7 MARKET NEWS) – FSD Pharma Inc. (NASDAQ:HUGE) stated, this morning, that interim results, for the first-in-human (“FIH”) single ascending dose Phase I clinical trial evaluating the Company’s novel drug candidate Lucid-21-302 (“Lucid-MS”), an orally-administered treatment for Multiple Sclerosis (“MS”), shows that the compound was well tolerated for the first 4 cohorts, with an addendum report describing the results of the fifth cohort due by the end of the month.

FSD Pharma is trading at $1.52, up $0.02 (+1.33%), on 311.69K shares traded.

Its 52-week range is $0.6181 to $2.10. It’s cleared several key inflection points on strong trading volume. Its key support levels are $1.53 and $1.50, while its key resistance levels are $1.70 and $1.75.

Connect with 24/7 …

The post FSD Pharma Interim Results Shows Lucid-MS Compound to be Safe and Well Tolerated appeared first on 24/7 Market News .

For further details see: